CrushSCI.com
117.1平均天数
127中位天数
12最短天数
219最长天数
3102025发文量

Paper Review Records

全部论文审稿周期

14 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

60 天

A contract research organization perspective on secondary pharmacology: current practices, panel selection, and emerging needs for interpretation

作者
Emilie Desfosses; Stéphanie A.D. Bonnet; Thierry Jolas展开收起
作者单位
Eurofins Discovery, 2 rue du Professeur Gargouïl, BP30001, 86600 Celle-Lévescault, France展开收起
PDF源文件 DOI 网页
48 天

Integration of safety pharmacology endpoints into toxicology studies - A survey of GLP institutions in China

作者
Bin Zhao; Chen Wang; Na Zhang; Ailing Zeng; Yaqin Peng; Wenqiang Zhang; Xuewu Liu; Jean-Pierre Valentin; Jennifer Pierson; Michael K. Pugsley; Jufeng Wang展开收起
作者单位
West China-Frontier PharmaTech Co., Ltd., Chengdu, China; Triapex Laboratory Co., Ltd., Nanjing, China; Pharmaron Beijing Co., Ltd., Beijing, China; College of Public Health, Sichuan University, Chengdu, China; Guangdong Lewwin Pharmaceutical Research Institute Co. Ltd., Guangdong, China; Hunan Prima Drug Research Center Co., Ltd., Changsha, China; UCB, Braine l'Alleud, Belgium; Health and Environmental Sciences Institute (HESI), Washington, DC, United States of America; Cytokinetics LLC., South San Francisco, CA, United States of America展开收起
PDF源文件 DOI 网页
34 天

Weight of evidence in safety pharmacology guidance: A case for explicit probabilistic reasoning in the revision of ICH S7A

作者
Derek J. Leishman; Michael K. Pugsley; Christopher P. Regan; Sridharan Rajamani; Michael G. Rolf; Eric I. Rossman; Jean-Pierre Valentin; Todd A. Wisialowski; Jill V. Nichols; Hugo M. Vargas展开收起
作者单位
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, United States of America; Cytokinetics, Toxicology & Safety Pharmacology, South San Francisco, CA, United States of America; Safety & Exploratory Pharmacology, Merck & Co., Inc., Rahway, NJ, United States of America; Johnson & Johnson Innovative Medicine, 3120 Merryfield Row, San Diego, CA 92121, United States of America; AstraZeneca R&D, Pepparedsleden 1, 431 83, Mölndal, Sweden; Labcorp Early Development Laboratories Inc., Madison, WI 53704, United States of America; Early Clinical Development & Translational Science, UCB, Braine-l'Alleud, Belgium; Pfizer Research and Development, Safety Pharmacology, Groton, CT 06340, United States of America; Amgen, Inc, Translational Safety & Risk Sciences, Thousand Oaks, CA, United States of America展开收起
PDF源文件 DOI 网页
219 天

Impact of filter selection on UPLC quantification of terbinafine hydrochloride: Optimization of sample preparation and method validation

作者
Giovanna Pereira Peressoni; Nicolly Bittencourt Guedes; Izabelle Amorim Ferreira Boza; Giovana Carolina Bazzo; Hellen Karine Stulzer展开收起
作者单位
Department of Chemistry, Center for Physical and Mathematical Sciences, Federal University of Santa Catarina, 88040-900 Florianópolis, SC, Brazil; Department of Pharmaceutical Sciences, Federal University of Santa Catarina, 88040-900 Florianópolis, SC, Brazil展开收起
PDF源文件 DOI 网页
194 天

Development of spectroscopic methods using charge transfer complex for the quantitative estimation of proguanil hydrochloride: Insights from greenness evaluation, BSA binding, molecular docking, antimicrobial studies and Insilico toxicity assessment

作者
Abdullah Mannan; Adila Khalil; Mohammad Kashif; Aliya Firdaus展开收起
作者单位
Analytical Chemistry Section, Department of Chemistry, Aligarh Muslim University, Aligarh, (U.P.) 202002, India; Bio-control Research Laboratory, Integral University, Kursi Road, Lucknow, (U.P.) 226026, India展开收起
PDF源文件 DOI 网页
12 天

Advancing safety pharmacology: Emerging technologies, innovative methods, and future directions

作者
Michael K. Pugsley; Brett R. Winters; Lutfiya Miller; Simon Authier; Michael J. Curtis展开收起
作者单位
Toxicology & Safety Pharmacology, Cytokinetics, South San Francisco, CA 94080, USA; 3rdAI LLC, Birmingham, AL, USA; Charles River Laboratories, Laval, QC H7V 4B3, Canada; Cardiovascular Division, King's College London, Rayne Institute, St Thomas' Hospital, London SE17EH, UK展开收起
PDF源文件 DOI 网页

FAQ

JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS审稿要多久?

截至2026-11-19,CrushSCI 收录了 JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS 的 14 篇完整审稿记录。最快一篇从收稿到录用用了 12 天(Advancing safety pharmacology: Emerging technologies, innovative methods, and future directions,2026-07-16 收稿,2026-07-28 录用),最慢一篇用了 219 天;平均 117.1 天,中位数 127 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。